Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers.
about
Clinical use of pharmacogenomic tests in 2009Pharmacological and Safety Profile of Dexlansoprazole: A New Proton Pump Inhibitor - Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific RegionTherapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectiveDetection of CYP2C19 Genetic Variants in Malaysian Orang Asli from Massively Parallel Sequencing DataPharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17Omeprazole-induced acute interstitial nephritis is not related to CYP2C19 genotype or CYP2C19 phenotype.Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect.Effect of icosapent ethyl (eicosapentaenoic acid ethyl ester) on omeprazole plasma pharmacokinetics in healthy adults.Drug-gene interactions: inherent variability in drug maintenance dose requirementsClinical application of pharmacogenomics.The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation.Recurrent CYP2C19 deletion allele is associated with triple-negative breast cancer.Clinical Impact of Cytochrome P450 2C19 Genotype on the Treatment of Invasive Aspergillosis under Routine Therapeutic Drug Monitoring of Voriconazole in a Korean Population.Helicobacter pylori virulence genes and host genetic polymorphisms as risk factors for peptic ulcer diseasePharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19.CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteersMolecular mechanisms of genetic variation and transcriptional regulation of CYP2C19.Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine.Genotype and allele frequency of CYP2C19*17 in a healthy Iranian populationInterindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase contentPharmacogenetics and cardiovascular disease--implications for personalized medicineEfavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent.Regulatory polymorphisms in CYP2C19 affecting hepatic expressionPolymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population: effects on clopidogrel response.Inhibition of the active principle of the weak opioid tilidine by the triazole antifungal voriconazoleIndividualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19.Effects of different omeprazole dosing on gastric pH in non-variceal upper gastrointestinal bleeding: A randomized prospective study.Indirect regulation of CYP2C19 gene expression via DNA methylation.Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review.Emerging roles for brain drug-metabolizing cytochrome P450 enzymes in neuropsychiatric conditions and responses to drugs.Breakthrough invasive fungal diseases during voriconazole treatment for aspergillosis: A 5-year retrospective cohort study.The impact of CYP2C19 polymorphisms on citalopram metabolism in patients with major depressive disorder.Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway.CYP2C19*17 affects R-warfarin plasma clearance and warfarin INR/dose ratio in patients on stable warfarin maintenance therapy.In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substratesRole of CYP2C9, CYP2C19 and EPHX Polymorphism in the Pharmacokinetic of Phenytoin: A Study on Uruguayan Caucasian Subjects.Pharmacogenetics and beyond: variability of voriconazole plasma levels in a patient with primary immunodeficiency.Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients.The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors.Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1.
P2860
Q24657536-C3D6B593-23AD-4E86-9941-680194C94A42Q26765113-B046057D-F90C-4CAC-91A8-EF06DA283460Q27009221-664AFDF4-9982-4B5D-AA22-AE062CF2EE28Q28553076-867EEC77-44A0-44DE-BB8E-609B6FD91829Q33692784-D65BA2D6-A0D5-43A1-8CEC-5BECBE8EE803Q33795077-17276901-80B6-4AE1-9246-F79E145195ECQ33891049-567329FD-CB92-4C4D-9E50-5DF4ABA2C9EAQ34130383-E3F8069D-229F-41F0-A156-FEE7E8146404Q34154939-ACE7FB12-A6A6-43D3-8850-FF1E33435E95Q34280685-75B52EAC-B673-40B8-9197-7D3F15B17232Q34457423-E760A63D-EB2F-4417-97B0-4DCB015E0187Q34695260-F41839F2-56DF-4B85-8432-FC3EAE216147Q35086478-EB659BC1-B5AE-4B5C-BB32-48D4CA36E349Q35809238-CA60F16D-A278-4C5C-AE55-5D1EFE97C0EFQ35952367-71E2F888-E3A6-401D-85E9-B06321281062Q36164941-F9E3A08E-E8D3-4465-A378-DE295C3FE9F5Q36307008-88418012-7729-4742-9489-57BA03CBD50BQ36390277-3D145906-D46F-4978-A45A-E4A3D4A9B40EQ36469405-DE954BD5-0D42-4509-989A-AE3841E06955Q36643041-290CC62D-081C-4D0B-8CB9-2539F483D171Q36974672-5EC81EC4-838A-4EC4-8B82-90FB536D3B7DQ37086418-ED6F733A-FFEA-4D32-8776-0A54576A941FQ37127419-016F5F5C-24DA-405D-8413-232F78C648DEQ37388236-1ABA9012-42FE-4396-813F-15DDFFC79069Q37471073-591CE2AE-B3A7-4F69-9CEB-797B8CB61AC9Q38032920-37CB5FF8-E1E8-4A74-8C87-254700913820Q38291290-BA60328A-1934-4DCA-AC8A-F396EAACE458Q38608601-9BCAF7A0-52AC-41A2-AE25-AE7612361F6EQ38726616-8D990DD0-902D-4DFC-935A-EBA85BD3A7CDQ38921093-C1D0D9D9-2F99-4D5C-9277-424704FAC953Q40562624-B55A468F-ED2E-4025-B3B4-A53C850E1740Q40569531-0C5299EE-DA09-4AD0-A0BE-57A1D5D42183Q41174078-83E563CE-F93E-4434-8F45-E2480C3E12C3Q41478624-2791DD59-D4DE-4F38-94F1-D9C684FB561EQ41986948-6B5F134F-4148-4708-A5C2-3CD177E6A0F2Q42098029-59E9A1C0-F284-47AB-9B77-9608DD342E0BQ42283754-73EA26E2-D875-4062-9784-C69CF4988E8DQ42370593-BD9E17F8-95C7-4086-A7B9-6457B8CBC5C6Q42424894-DAA11E0E-202A-4BF8-9D00-1256594A108CQ42710782-C672808B-86AC-4CC5-8480-C53366999C29
P2860
Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Increased omeprazole metabolis ...... c study in healthy volunteers.
@ast
Increased omeprazole metabolis ...... c study in healthy volunteers.
@en
type
label
Increased omeprazole metabolis ...... c study in healthy volunteers.
@ast
Increased omeprazole metabolis ...... c study in healthy volunteers.
@en
prefLabel
Increased omeprazole metabolis ...... c study in healthy volunteers.
@ast
Increased omeprazole metabolis ...... c study in healthy volunteers.
@en
P2093
P2860
P1476
Increased omeprazole metabolis ...... c study in healthy volunteers.
@en
P2093
Erik Eliasson
Jessica Mwinyi
R Michael Baldwin
Rasmus Steen Pedersen
Staffan Ohlsson
P2860
P304
P356
10.1111/J.1365-2125.2008.03104.X
P407
P577
2008-02-20T00:00:00Z